FSTX insider filings
F-star Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-03-09. Screen FSTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for FSTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — F-star Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-03-09 | 4 | Kayitalire Louis — CHIEF MEDICAL OFFICER | Code (U): 29,236 @ $7.12 · Disposition to issuer (D): 25,019 @ $7.12 · Disposition to issuer (D): 27,289 (derivative) · Disposition to issuer (D): 12,880 (derivative) · Disposition to issuer (D): 53,634 (derivative) · Disposition to issuer (D): 35,719 (derivative) | EDGAR |
| 2023-03-09 | 4 | Forster Eliot — PRESIDENT AND CEO, Director | Code (U): 347,578 @ $7.12 · Disposition to issuer (D): 73,959 @ $7.12 · Disposition to issuer (D): 127,924 (derivative) · Disposition to issuer (D): 165,028 (derivative) · Disposition to issuer (D): 126,909 (derivative) | EDGAR |
| 2023-03-09 | 4 | Klein Pamela M. — Director | Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Other (J): 15,000 (derivative) · Other (J): 7,500 (derivative) | EDGAR |
| 2023-03-09 | 4 | Brady Todd C — Director | Code (U): 15,004 @ $7.12 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Other (J): 11,000 (derivative) · Other (J): 10,964 (derivative) · Other (J): 5,500 (derivative) · +3 more | EDGAR |
| 2023-03-09 | 4 | Brewis Neil — CHIEF SCIENTIFIC OFFICER | Code (U): 105,088 @ $7.12 · Disposition to issuer (D): 9,375 @ $7.12 · Disposition to issuer (D): 22,561 (derivative) · Disposition to issuer (D): 74,263 (derivative) · Disposition to issuer (D): 132,469 (derivative) | EDGAR |
| 2023-03-09 | 4 | Race Geoffrey — Director | Code (U): 3,937 @ $7.12 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2023-03-09 | 4 | Benz Edward JR — Director | Disposition to issuer (D): 4,385 @ $7.12 · Disposition to issuer (D): 3,937 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2023-03-09 | 4 | Bermingham Nessan — Director | Code (U): 97,547 @ $7.12 · Disposition to issuer (D): 6,328 @ $7.12 · Disposition to issuer (D): 34,111 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2023-03-09 | 4 | Arkowitz David — Director | Code (U): 8,386 @ $7.12 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Other (J): 10,000 (derivative) · Other (J): 5,500 (derivative) · Other (J): 4,386 (derivative) · +4 more | EDGAR |
| 2023-03-09 | 4 | DEPTULA-HICKS DARLENE M — See Remarks | Code (U): 30,898 @ $7.12 · Disposition to issuer (D): 25,539 @ $7.12 · Disposition to issuer (D): 28,426 (derivative) · Disposition to issuer (D): 25,894 (derivative) · Disposition to issuer (D): 59,823 (derivative) · Disposition to issuer (D): 24,902 (derivative) | EDGAR |
| 2023-01-09 | 4 | Race Geoffrey — Director | Option exercise (M): 3,937 @ $0.11 · Option exercise (M): 3,937 (derivative) @ $0 | EDGAR |
| 2022-08-02 | 4 | Forster Eliot — President and CEO, Director | Option exercise (M): 260,977 @ $0.11 · Option exercise (M): 32,602 (derivative) @ $0 · Option exercise (M): 228,375 (derivative) @ $0 | EDGAR |
| 2022-08-02 | 4 | Brewis Neil — Chief Scientific Officer | Option exercise (M): 76,619 @ $0.11 · Option exercise (M): 6,307 (derivative) @ $0 · Option exercise (M): 70,312 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Brady Todd C — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Race Geoffrey — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Benz Edward JR — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Klein Pamela M. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Bermingham Nessan — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Arkowitz David — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Forster Eliot — President and CEO, Director | Grant/award (A): 126,909 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Kayitalire Louis — Chief Medical Officer | Grant/award (A): 35,719 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Brewis Neil — Chief Scientific Officer | Grant/award (A): 132,469 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | DEPTULA-HICKS DARLENE M — Treasurer and CFO | Grant/award (A): 24,902 (derivative) @ $0 | EDGAR |
| 2022-01-11 | 4 | Kayitalire Louis — Chief Medical Officer | Grant/award (A): 53,634 (derivative) @ $0 | EDGAR |
| 2022-01-11 | 4 | Brewis Neil — Chief Scientific Officer | Grant/award (A): 74,263 (derivative) @ $0 | EDGAR |
| 2022-01-11 | 4 | Forster Eliot — President and CEO, Director | Grant/award (A): 165,028 (derivative) @ $0 | EDGAR |
| 2022-01-11 | 4 | DEPTULA-HICKS DARLENE M — Treasurer and CFO | Grant/award (A): 59,823 (derivative) @ $0 | EDGAR |
| 2021-11-04 | 4 | Kayitalire Louis — Chief Medical Officer | Sale (S): 39 @ $6.81 · Sale (S): 25 @ $6.85 | EDGAR |
| 2021-10-06 | 4 | Kayitalire Louis — Chief Medical Officer | Sale (S): 64 @ $7.23 | EDGAR |
| 2021-08-24 | 4/A | Kayitalire Louis — Chief Medical Officer | Grant/award (A): 26,437 @ $0 | EDGAR |
| 2021-08-24 | 4/A | Bermingham Nessan — Director | Grant/award (A): 16,875 @ $0 | EDGAR |
| 2021-08-24 | 4/A | DEPTULA-HICKS DARLENE M — Treasurer and CFO | Grant/award (A): 26,437 @ $0 | EDGAR |
| 2021-07-07 | 4 | Kayitalire Louis — Chief Medical Officer | Sale (S): 1,054 @ $8.43 | EDGAR |
| 2021-06-07 | 4 | Krol Patrick Johan Hendrik — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Klein Pamela M. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Brady Todd C — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Race Geoffrey — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Benz Edward JR — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Bermingham Nessan — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | Arkowitz David — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Kayitalire Louis — Chief Medical Officer | Grant/award (A): 12,880 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Forster Eliot — President and CEO, Director | Grant/award (A): 127,924 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Brewis Neil — Chief Scientific Officer | Grant/award (A): 22,561 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | DEPTULA-HICKS DARLENE M — Treasurer and CFO | Grant/award (A): 25,894 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Brewis Neil — Chief Scientific Officer | Grant/award (A): 18,000 @ $0 | EDGAR |
| 2021-02-02 | 4 | Forster Eliot — President and CEO, Director | Grant/award (A): 142,000 @ $0 | EDGAR |
| 2021-02-02 | 4 | Kayitalire Louis — Chief Medical Officer | Grant/award (A): 29,000 @ $0 | EDGAR |
| 2021-02-02 | 4 | Benz Edward JR — Director | Grant/award (A): 4,385 @ $0 | EDGAR |
| 2021-02-02 | 4 | Bermingham Nessan — Director | Grant/award (A): 87,000 @ $0 | EDGAR |
| 2021-02-02 | 4 | DEPTULA-HICKS DARLENE M — Treasurer and CFO | Grant/award (A): 30,000 @ $0 | EDGAR |
Recent 8-K events — F-star Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-03-09 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events | EDGAR |
| 2023-02-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-29 | 8-K | 8.01 — Other Events | EDGAR |
| 2022-12-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-12-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FSTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs